BioTime (NYSE MKT, TASE: BTX) priced a public offering of 9,615,385 common shares at a price of $2.60 each for gross proceeds of about $25-million.Read More
Profound Medical (TSXV:PRN; OTCQX:PRFMF) closed a bought deal financing for total proceeds of $10-million.Read More
Profound Medical (OTCQB:PRFMF; TSXV:PRN) reported second quarter revenue of $957,139, compared to nil in the year ago quarter, but up 62% from $591,517 in the first quarter of 2017.Read More
GeneNews (TSX:GEN) has signed a binding commitment letter with Milost Global, which will initially purchase up to $3-million in unsecured convertible notes from GeneNews, as part of an equity and debt subscription agreement of up to $10-million.Read More
Vital Therapies (NASDAQ:VTL) has priced a public offering of 8,750,000 newly issued common share at a price of $4 each for gross proceeds of approximately $35-million.Read More
Athersys (NASDAQ:ATHX) priced a public offering of 19,802,000 common shares at a price of $1.01 each for gross proceeds of about $20-million and gave underwriters an option to purchase up to an additional 2,970,300 shares.Read More
3D Signatures (TSX-V:DXD) issued 5,187,618 units under a brokered private placement at a price of 75 cents a unit for gross proceeds of about $3.9-million, including a partial exercise of an over-allotment option.Read More
Profound Medical (TSX-V:PRN) has completed a bought deal offering of 15.82 million common shares at a price of $1.10 each for gross proceeds of about $17.4-million.
The offering was completed through a syndicate of underwriters led by GMP Securities, and included Echelon Wealth Partners and Mackie Research Capital.Read More
Avivagen (TSX-V:VIV) has completed a private placement of brokered and non-brokered components, selling 60 million units for gross proceeds of $3.6-million.
Each unit consists of one common share and one-half of a warrant at a price of six cents a unit. Each whole warrant entitles the holder to acquire one common share of Avivagen at a price of nine cents for two years from closing.Read More
TearLab (NASDAQ:TEAR; TSX:TLB) has priced a public offering of common stock to raised gross proceeds of approximately $17.3-million to close on May 9.
The offering was priced at 75 cents a share of common stock, or common stock equivalent, with each share of common stock coupled with a warrant to purchase one-half of one share of common stock.Read More
GeneNews (TSX:GEN) has closed the first tranche of a private placement, consisting of the issuance of approximately 5.6 million common shares at a price of 10 cents each, for gross proceeds of approximately $560,000, to be used for working capital.
The company also has executed a term sheet with Alumina Partners for a second tranche, allowing GeneNews to draw down on $10-million (US) in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period.Read More
GeneNews (TSX:GEN) is undertaking a non-brokered private placement of up to 50 million common shares at a price of 10 cents apiece, or $5-million.
Any remaining unfunded portion of the offering may be raised with the issuance of a senior secured, collateralized convertible debenture. If needed, this convertible debenture would be issued with a term of one year, interest accrued and payable at 15% and with a conversion price of 16 cents a share. The conversion would become mandatory if the common stock trades above 16 cents for 30 consecutive trading days.Read More
Titan Medical (OTCQX:TITXF; TSX:TMD) has closed a public offering of 11,670,818 units at a price of 90 cents each for gross proceeds of $10.5-million.
Each unit consists of one common share and one warrant, with each warrant exercisable to purchase an additional common shares at a price of $1 for a period of 60 months.Read More